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Ebola virus infection of humans is associated with high levels of circulating inflammatory chemokines and cytokines. We
demonstrate that direct infection of human PBMC results in the induction of MCP-1, MIP-1a, RANTES, and TNF-a as early
as 24 h p.i. in response to live virus. Monocyte-derived macrophages infected with live Ebola-virus secreted MIP-1a and
TNF-a specifically while RANTES and MCP-1 were secreted by with both live or inactivated virus stimulation and do not
require viral replication. Type I interferons (IFN-a and -b), IL-1b and IL-10, were not induced by Ebola virus. Furthermore, live
virus infection of both PBMCs and monocytes-derived macrophages inhibited IFN-a induced by double-stranded RNA in vitro.
These data provide the first direct evidence of a role for macrophages in the pathogenesis to Ebola virus and suggest that
Ebola virus can inhibit cellular antiviral mechanisms mediated by type I interferons. © 2001 Academic Press
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Ebola virus is the etiologic agent of a severe hemor-
rhagic fever of humans. It is a member of the filovirus family
that includes Ebola virus (including four subtypes: Zaire,
Sudan, Ivory Coast, and Reston) and Marburg virus (Peters
et al., 1996). Ebola Zaire virus infection of humans and
non-human primates results in a rapidly progressive, se-
vere illness characterized by bleeding, capillary leakage,
multisystem dysfunction, and a shock-like state culminating
in death in ;80% of infected individuals (Bwaka et al., 1999;
Peters and LeDuc, 1999). There is no effective treatment at
present, although some studies have suggested that trans-
fer of immune sera or certain monoclonal antibodies di-
rected against the glycoprotein (GP) or nucleoproteins (NP)
of Ebola virus may ameliorate the illness and prevent death
(Mupapa et al., 1999; Xu et al., 1998).
Studies aimed at understanding the biology of this virus
and the mechanisms of pathogenesis in humans and ani-
mal models have suggested that mononuclear phagocytic
cells and endothelial cells are sites of early replication and
likely play a crucial role in the pathogenesis of Ebola hem-
orrhagic fever (Connolly et al., 1999; Geisbert et al., 2000;
abel, 1999; Schnittler and Feldmann, 1998; Schnittler et al.,
993; Yang et al., 1998). Infection of monocytes and macro-
hages by Marburg virus results in activation and secretion
f tumor necrosis factor (TNF2)-a. Infection of endothelial
1 To whom reprint requests should be addressed.
2 Abbreviations used: PBMC, peripheral blood mononuclear cells;LPS, lipopolysaccharide; IFN, interferon; IL, interleukin; MCP, macro-
phage chemotattractant protein; MIP, macrophage inflammatory pro-
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20cells with Ebola virus inhibits antigen presentation (Class I)
pathways (Harcourt et al., 1998, 1999) and may cause the
inhibition of cellular immune responses, a feature of fatal
human infections (Baize et al., 1999).
Evidence for the involvement of inflammatory media-
tors in the pathogenesis of Ebola virus infection specif-
ically has come from the study of both symptomatic and
asymptomatic infected individuals who have been found
to have circulating TNF-a, IL-1b, IL-6, MIP-1a, and
CP-1 (Leroy et al., 2000; Villinger et al., 1999). However,
n these descriptive studies, the sources of these cyto-
ines and chemokines were not determinable, and direct
vidence for the production of inflammatory mediators by
onocytes/macrophages infected with Ebola virus is
acking to date.
In this study, we have investigated the direct effect of
bola virus infection on human macrophages. Circulat-
ng inflammatory cytokines and chemokines that were
etected in the sera from infected humans were also
ound to be secreted by human macrophages infected in
itro with Ebola Zaire. Infected macrophages were
hown to secrete high levels of TNF-a and MCP-1 but not
IL-1b or IL-10. Unexpectedly, type I interferons [interferon
IFN)-a and -b] were not produced by infected macro-
hages in vitro despite elevated levels of these two
ytokines in the sera of Ebola patients, suggesting that
bola virus is capable of inhibiting cellular antiviral de-
enses in these cells.tein; MOI, multiplicity of infection; RANTES, Regulated upon activation
normal T-cell expressed and secreted; TNF, tumor necrosis factor.
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21CYTOKINES AND CHEMOKINES IN HUMAN EBOLA VIRUS INFECTIONRESULTS
irculating IFN-a, IFN-b, TNF-a, and MCP-1 are
elevated in Ebola virus infection
Sera collected from patients were analyzed for the
presence of a number of chemokines and cytokines
that mediate inflammation or chemotaxis of inflamma-
tory cells. Of serum samples from nine Ebola patients
tested, seven individuals were in the acute phase of
infection, based on antigen, IgM, and/or IgG positivity.
All patients in the acute phase of disease had detect-
able IFN-a and IFN-b in their sera (Table 1). Six of
these seven patients had elevated MCP-1, and three of
these also had high levels of TNF-a and MIP-1a (Table
1). Of the two Ebola Ag-negative patients, one was in
the recovery phase since the serum was positive for
anti-Ebola IgM and another in convalescent phase,
being positive for anti-Ebola IgG only (Table 1). The
patient who was in the recovery phase had elevated
IFN-b, TNF-a, and MIP-1a in serum; however, both the
patients had lower levels of IFN-a compared to acute-
phase patients. Three of the seven acute-phase pa-
tients had elevated levels of MIP-1a unrelated to the
resence or absence of Ebola Ag (Table 1). Of note,
he mean RANTES level in the sera from Ebola pa-
ients was not significantly different from that of
he (uninfected) control sera. Thus, the elevation of
ANTES may be nonspecific, representing activation
f the innate immune system by coincidental inflam-
atory or infectious stimuli other than Ebola virus. In
ummary, acute-phase patients have higher levels of
FN-a and MCP-1 than uninfected controls, corre-
sponding with the presence of viral antigens.
T
Levels of Circulating Inflammatory Cytokines
Patient
Ebola serologya
Agc IgM IgG MCP-1 (ng/ml) MIP-1a (ng/m
1 2 2 1 10.790 —
2 2 1 1 — 5.424
3 1 1 1 — —
4 1 1 2 8.59 —
5 1 1 2 10.17 3.11
6 1 2 2 4.40 —
7 1 2 2 5.12 —
8 1 2 2 28.12 5.24
9 1 2 2 40.59 39.87
Uninfected serad 2.66 6 1.82 1.89 6 4.13
a Serology for Ebola antigens (Ag), IgM, and IgG was performed as
b Cytokine/chemokine levels were measured by ELISA as described
c Ebola Ag titers.
d Mean 6 SD for six sera from uninfected African individuals.Ebola infection of PBMC in vitro stimulates secretion
of inflammatory and chemotactic mediators
The contribution of monocytes and lymphocytes to the
production of inflammatory mediators detected in pa-
FIG. 1. Ebola virus infection of human PBMC induces MCP-1, MIP-1a,
RANTES, and TNF-a. Human PBMC were infected with 0.5 m.o.i. of live
(E) or irradiated Ebola Zaire 1976 live (5 3 106 rads; F) or incubated
ith lipopolysaccharide (10 ng/ml; ) or medium alone (n). Superna-
ants collected at 24, 38, 48, or 68 h were assayed for MCP-1, MIP-1a,
ANTES, and TNF-a by ELISA.
iated with Ebola Virus Infection in Humans
Cytokine/chemokineb
ANTES (ng/ml) TNF-a (ng/ml) IFN-a (ng/ml) IFN-b (IU/ml)
— — 0.156 5,178
— 4.207 0.048 22,802
— — 0.25 420
— — 1.50 4,181
— 10.33 0.40 6,367
— — 1.16 1,297
— — 1.14 6,001
— 6.80 1.12 13,552
76.08 12.68 0.45 1,050
25.83 6 5.08 2.74 6 1.61 0 0
ed under Materials and Methods.
Materials and Methods.ABLE 1
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22 GUPTA ET AL.tients with Ebola was investigated by analysis of PBMC
supernatants following in vitro infection with Ebola Zaire
1976. PBMCs from uninfected volunteers were infected
in vitro with various m.o.i.’s of Ebola Zaire 1976. Infection
with live virus selectively induced secretion of MCP-1,
MIP-1a, RANTES, and TNF-a as early as 24 h p.i. (Fig. 1).
n contrast, IL-1b and IL-10 secretion was not stimulated
by live or killed Ebola virus (data not shown). TNF-a,
IP-1a, and RANTES were induced by both live and
FIG. 2. Human monocytes-derived macrophages infected with Ebola
virus specifically secrete MIP-a and TNF-a. Monocyte-derived macro-
hages (see Materials and Methods) were infected with live Ebola
aire 1976 (0.5 m.o.i.; F), irradiated Ebola Zaire 1976 (5 3 106 rads; E)
r medium alone (). Supernatants collected at 30, 60, or 72 h were
ssayed for MIP-1a, TNF-a, RANTES, and MCP-1 by ELISA.
FIG. 3. Ebola virus infection inhibits poly-IC induced IFN-a in vitro). (A
1976 (0.05 m.o.i.; E) were induced with 100 mg/ml (n) or 25 mg/ml () poly
(). (B) Monocyte-derived macrophages (see Materials and Methods) w
(l) poly-IC or uninfected cells (F) treated with 50 mg/ml (L) poly-IC. Supern
ELISA. Sensitivity of the IFN-a ELISA is 10 pg/ml.illed virus in the supernatants collected at the earlier
ime points (24–38 h); however, the levels of these cyto-
ines and chemokines declined with further incubation
ith killed virus alone (Fig. 1). These findings suggest
hat sustained release of these inflammatory mediators
equires ongoing viral replication.
nfection of macrophages with Ebola virus stimulates
NF-a and MIP-1a but not IFN-a, IFN-b, IL-1b,
r IL-10
Ebola virus replicates in macrophages, endothelial
ells, and fibroblasts early in the course of viral infection.
herefore we were interested in the patterns of inflam-
atory and anti-viral cytokines in cultures of macroph-
ge-enriched PBMCs. Human monocytes (85–90% CD14
ositive) were cultured for 6–7 days to allow differentia-
ion into macrophages. Figure 2 indicates that infection
ith live virus stimulates high levels of MIP-1a and
NF-a at 30 and 60 h p.i. with a gradual decline over the
72 h of culture. We have also determined the levels of
IL-1b, IFN-a, IFN-b, and IL-10, but these cytokines were
not detected in culture supernatants stimulated with ei-
ther live or killed virus. As observed with PBMCs,
RANTES and MCP-1 were also detected with both live
and killed virus infection, suggesting that the release of
these chemokines from macrophages do not require
viral replication. These data suggest that Ebola virus
infection of macrophages results in the secretion of in-
flammatory and chemotactic cytokines/chemokines and
a simultaneous inhibition of cellular anti-viral activity.
Infection with live Ebola virus inhibits poly-IC-induced
IFN-a secretion
To determine whether Ebola virus fails to induce or
ctively blocks type I interferon secretion, we used
levels in supernatants of human PBMCs infected with live Ebola Zaire
ninfected cells (F) were treated with 100 mg/ml (e) or 25 mg/ml poly-IC
fected with live Ebola Zaire 1976 (0.05 MOI; E) induced with 50 mg/ml) IFN-a
-IC or u
ere inatants collected at 24, 48, and 72 h were assayed for IFN-a levels by
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23CYTOKINES AND CHEMOKINES IN HUMAN EBOLA VIRUS INFECTIONpoly-IC to stimulate IFN-a production by PBMCs and
monocyte-derived macrophages (MDCs). IFN-a secre-
ion induced by different doses of poly-IC (25–100 mg/ml)
n uninfected PBMC and macrophages were compared
ith those in Ebola-infected cells. Our results (Fig. 3)
how that poly-IC induces a time-dependent secretion of
FN-a from both MDCs and PBMCs that is completely
locked when cells are infected with live Ebola virus.
nfection with virus alone did not induce levels of IFN-a
above medium controls at 24 and 48 h p.i. However, very
low levels of IFN-a are detected in infected cells, above
edium controls, at 72 h in both PBMCs and MDCs
ultures (225 and 301 pg/ml, respectively). These data
ndicate that the double-stranded RNA-dependent path-
ay for IFN-a secretion is blocked by Ebola virus.
DISCUSSION
High levels of circulating inflammatory cytokines, spe-
ifically IFN-g, TNF-a, and IL-6, have been demonstrated
previously in the sera of Ebola patients during the acute
phase of illness (Villinger et al., 1999). Our results from
nfected patients confirm that the virus induces high
evels of inflammatory (TNF-a, MCP-1) and anti-viral (type
interferons) cytokines during acute infection. A study of
symptomatic and antigen-positive Ebola patients (Leroy
t al., 2000) also demonstrated elevated levels of IL-1b,
IL-6, TNF-a, MCP-1, MIP-1a, and MIP-1b, suggesting that
iral replication is associated with induction of these
nflammatory mediators. Our data show that infection of
BMCs and macrophages by Ebola virus induces many
f these mediators, thus providing direct, albeit in vitro,
vidence for a role of macrophages in the pathogenesis
f the disease. However, our data also indicate that other
ources of inflammatory cytokines and chemokines are
mportant in Ebola hemorrhagic fever because the in-
ected macrophages in culture do not secrete some of
he mediators that we and others (Baize et al., 1999;
eroy et al., 2000; Villinger et al., 1999) have observed in
era from infected patients.
Investigators have previously proposed that inflamma-
ory mediators may participate in the pathogenesis of
ilovirus hemorrhagic fevers through their effects on en-
othelial cell function (Feldmann et al., 1999; Schnittler
nd Feldmann, 1998, 1999). Supernatants of Marburg
irus-infected macrophages have been shown to in-
rease endothelial cell permeability via induction of
NF-a (Schnittler and Feldmann, 1999). Direct damage to
ndothelial cell integrity proposed to be caused by Ebola
lycoprotein (GP1) (Yang et al., 1998). Thus the secretion
f inflammatory cytokines and chemokines may work in
oncert with Ebola viral proteins to trigger an increase in
ermeability of endothelial cells, a crucial feature of
ilovirus-associated hemorrhagic fevers. Our results in-
icate that macrophages and PBMC cultures infected
ith Ebola virus secrete high levels of TNF-a, suggesting chat these cells may be a major source of inflammatory
ytokines during infection.
MCP-1 is a major chemoattractant involved in recruit-
ent of macrophages (Lu et al., 1998). Studies in HIV
atients suggest a correlation between viral replication
nd MCP-1 levels (Bisset et al., 1997). Our study also
hows that high levels of MCP-1 are associated with live
bola virus infection of PBMCs and macrophages. Since
acrophages are an important target of Ebola virus
eplication, it is conceivable that the filoviruses may
xploit the chemotactic properties of these and other
hemokines for its own propagation within the host.
IP-1a and RANTES, two other chemokines induced by
nfection of macrophages with Ebola, function as che-
oattractants for lymphocytes, neutrophils, and eosino-
hils and could be important in the early host response
o the virus.
Interferons (IFNs) play an important role in first anti-
iral defense function as is evident by the fact that
nti-IFN strategies are present in most viruses. Virus
locks induction of IFNs either by interfering with Janus
inase, signal transducers and activator pathways or by
nhibiting the activation of IFN effector pathways. This is
chieved by blocking double-stranded (ds) RNA-depen-
ent protein kinase activation, e.g., by the NS1 protein of
nfluenza virus (Bergmann et al., 2000), or inhibiting phos-
horylation of eukaryotic translation initiation factor-a
(eIF-2a) like by vaccinia virus (Smith, 1999) or inducing
RNase L inhibitor as shown in HIV (Goodbourn et al.,
2000). Ebola virus has been shown to inhibit Class I
upregulation in endothelial cells induced by IFN-a and
IFN-g in vitro (Harcourt et al., 1999). In a recent report,
viral protein 35 (VP35) of Ebola virus has been shown to
inhibit type I interferon production by inhibiting dsRNA
synthesis (Basler et al., 2000). Our data showing lack of
induction of type I interferon are consistent with these
reports. We have also shown that Ebola virus inhibits the
dsRNA-dependent pathway for IFN-a induction by mac-
rophages and PBMCs, suggesting a possible mecha-
nism for escape from early anti-viral defenses, which
allows rapid viral replication and spread. Another impli-
cation of our in vitro observations is that the high levels
f type I interferons observed in the sera of Ebola virus-
nfected individuals (Table 1) are likely to be derived from
onmacrophage sources, like endothelial cells, hepato-
ytes, or epithelial cells, known replication sites of Ebola
irus. Thus our the first direct evidence of potential
echanisms by which macrophages can initiate or prop-
gate the vascular pathology associated with Ebola virus
nfections.
MATERIALS AND METHODS
atient population and serum samplesBlood specimens from nine individuals who fulfilled
linical and serological criteria for Ebola hemorrhagic
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24 GUPTA ET AL.fever (Ksiazek et al., 1999; Roels et al., 1999; Rowe et al.,
999) were included in the study. The patients fell into
wo groups based on serum viral antigen (Ag) status.
even patients were positive for viral Ag by capture
LISA, and two were negative for viral Ag but positive for
nti-Ebola IgM or IgG. The first group was considered to
e in the early phase of infection and the second, in the
ater, convalescent phase (Ksiazek et al., 1999). Blood
amples were collected between 1 and 19 days after
nset of symptoms. The study population consisted of
ive males and four females, aged between 22 and 56
ears. Blood was drawn at the bedside, and sera were
eparated on a bench-top centrifuge and frozen imme-
iately in liquid nitrogen for transportation to the Centers
or Disease Control and Prevention (CDC), Atlanta, GA.
t the CDC, samples were irradiated with a Co60 irradi-
ator on dry ice (5 3 106 rad; Gammacell; Kanata, Canada)
and stored at 270°C until further processing. As control
sera, we used sera from six uninfected (sero-negative)
individuals collected in an unrelated village sero-survey
for hemorrhagic fevers in West Africa (Sierra Leone).
These sera were processed and transported in a similar
manner to those from Ebola patients. This study adhered
to the ethical and institutional guidelines for human stud-
ies of the Centers for Disease Control and Prevention,
Atlanta, GA, and all study participants provided written or
verbal consent before inclusion in the study.
Derivation of macrophages from peripheral blood
mononuclear cells
For generation of macrophages from monocytes,
blood was collected from healthy volunteer donors by
phlebotomy. Peripheral blood mononuclear cells
(PBMCs) were separated by density gradient centrifuga-
tion over Ficoll–Paque (Amersham Pharmacia Biotech
AB, Uppsala, Sweden) as recommended by the manu-
facturer. Mononuclear cells were separated from lym-
phocytes by a plastic adherence technique as follows.
PBMCs suspended in RPMI medium with 5% fetal calf
serum were incubated on 100- to 150-mm Petri plates for
1 h for adherence. Nonadherent cells were removed by
repeated washing, and adherent cells were subse-
quently removed using cell scrapers and transferred to
48-well plates at a concentration of 1 3 105 cells/well in
PMI supplemented with autologous human plasma.
he adherent cells were cultured for 6–7 days to obtain
acrophage-like morphology. Adherent cells were
ested for purity by flow cytometry (FACScan Flow cytom-
ter, Becton-Dickinson, San Jose, CA) using a monocyte-
pecific antibody CD14 (Pharmingen, San Diego, CA).
nfection protocol
All infections were performed in a Biosafety level 4
BSL4) laboratory at the Centers for Disease Control and
revention, Atlanta, GA. Frozen supernatants of infectedells were irradiated (5 3 106 rad as described above) to
nactivate virus before use in assays. Monocyte-derived
acrophages (MDC) were infected with m.o.i. of 0.5 of
ive or g-radiated Ebola virus (Ebola Zaire1976; CDC No.
08473) for 40 min. Nonadsorbed viral particles were
emoved, and fresh RPMI medium containing autologous
erum was added for a further incubation of #72 h. In
ome experiments, cells were stimulated with LPS (10
g/ml) and allowed to remain in culture #72 h. Super-
atants collected at the indicated time points were as-
ayed for chemokines and cytokines (see below). For
nduction of IFN-a by poly-IC, both PBMCs and MDC
were treated with 100, 50, or 25 mg/ml concentration of
poly-IC with or without infection with Ebola virus (as
mentioned above). Supernatants were collected at 24,
48, and 72 h and assayed for human IFN-a using an
ELISA kit.
Chemokine/cytokine assays
Human serum samples and culture supernatants col-
lected from infected and uninfected macrophages were
assayed for cytokines and chemokines using commer-
cially available ELISA kits for TNF-a, MCP-1, MIP-1a,
ANTES, IL-1b, IL-10 (all from R&D, Minneapolis, MN),
FN-a, and IFN-b (both from Biosource International,
Camarillo, CA) using manufacturer (s) recommendations.
Values were expressed in pg/ml (for MCP-1) or ng/ml (for
IFN-a, TNF-a, MIP1-a RANTES) and IU/ml (for IFN-b).
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